↓ Skip to main content

Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients

Overview of attention for article published in Alimentary Pharmacology & Therapeutics, December 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (58th percentile)

Mentioned by

twitter
5 tweeters

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients
Published in
Alimentary Pharmacology & Therapeutics, December 2016
DOI 10.1111/apt.13893
Pubmed ID
Authors

Angelison, L., Almer, S., Eriksson, A., Karling, P., Fagerberg, U., Halfvarson, J., Thörn, M., Björk, J., Hindorf, U., Löfberg, R., Bajor, A., Hjortswang, H., Hammarlund, P., Grip, O., Torp, J., Marsal, J., Hertervig, E.

Abstract

Real-life long-term data on infliximab treatment in ulcerative colitis are limited. To study the long-term efficacy and safety of infliximab in chronic active ulcerative colitis and possible predictors of colectomy and response were also examined. A retrospective multi-centre study of infliximab treatment in 250 patients with chronic active ulcerative colitis with inclusion criteria: age ≥18 years, ambulatory treated, steroid-dependent or intolerant and/or immunomodulator refractory or intolerant. Steroid-free clinical remission was achieved by 123/250 patients (49.2%) at 12 months and in 126/250 patients at a median follow-up of 2.9 years (50.4%). Primary response at 3 months was achieved by 190/250 (76.0%) patients and associated with a high probability of response 168/190 (88.4%) at 12 months and 143/190 (75.3%) at follow-up. Long-term rate of colectomy in primary responders was 6/190 (3.2%) at 12 months and 27/190 (14.2%) at last follow-up. Failure to achieve response at 3 months was associated with a high risk of subsequent colectomy, 29/60 (48.3%) at 12 months and 41/60 (68.3%) at follow-up. Response at 12 months was associated with a low risk of subsequent colectomy, 14/181 (7.7%) compared with non-response 19/34 (55.9%) (P < 0.0001). Non-response at 3 months was an independent predictor of subsequent colectomy (HR = 9.40, 95% CI = 5.10-17.35, P < 0.001). Concomitant azathioprine therapy did not influence outcome in terms of colectomy. Long-term efficacy of infliximab treatment in chronic active ulcerative colitis is excellent especially in patients who respond to induction treatment. Conversely, non-response at 3 months predicts a poor outcome, with a high risk of subsequent colectomy.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Librarian 1 13%
Unknown 7 88%
Readers by discipline Count As %
Medicine and Dentistry 1 13%
Unknown 7 88%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2017.
All research outputs
#3,300,854
of 7,987,814 outputs
Outputs from Alimentary Pharmacology & Therapeutics
#1,537
of 2,504 outputs
Outputs of similar age
#103,054
of 253,901 outputs
Outputs of similar age from Alimentary Pharmacology & Therapeutics
#41
of 61 outputs
Altmetric has tracked 7,987,814 research outputs across all sources so far. This one has received more attention than most of these and is in the 58th percentile.
So far Altmetric has tracked 2,504 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,901 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 58% of its contemporaries.
We're also able to compare this research output to 61 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.